Cerevel Therapeutics Holdings, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2019 to 2023.
  • Cerevel Therapeutics Holdings, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $4.48M, a 212% increase year-over-year.
  • Cerevel Therapeutics Holdings, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $549M, a 12% decline from 2022.
  • Cerevel Therapeutics Holdings, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $623M, a 47.1% increase from 2021.
  • Cerevel Therapeutics Holdings, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $424M, a 3.91% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $549M -$74.6M -12% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $623M +$200M +47.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $424M -$17.2M -3.91% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $441M +$381M +634% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-22
2019 $60.1M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.